A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Boston Children's Hospital

Status and phase

Completed

Phase 2

Conditions

Hutchinson-Gilford Syndrome

Progeria

Treatments

Drug: Zoledronic Acid

Drug: Pravastatin

Drug: Lonafarnib

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00879034

09-02-0074

P06087 (Other Identifier)

Details and patient eligibility

About

This is an open label single arm feasibility trial. A combination of two oral agents (pravastatin and lonafarnib) and one intravenous (IV) agent (zoledronic acid) will be administered at doses and schedule currently applied in pediatrics. These agents all target farnesylation pathways at different points. Our goal is to inhibit farnesylation of abnormal lamin, the disease-causing protein in Hutchinson-Gilford Progeria Syndrome and progeroid laminopathies (henceforth "progeria"). The drugs will include the intravenous bisphosphonate zoledronic acid, oral HMG co-reductase inhibitor pravastatin and the oral farnesyltransferase inhibitor (FTI) lonafarnib (SCH 66336). Patients with genetically confirmed progeria will be eligible for this protocol. Treatment will be initiated for 4 weeks duration and may be extended depending on tolerability. This study will assess the feasibility of this treatment regimen in the first 4 weeks. If tolerated for 4 weeks, patients can be treated with this regimen for up to 6 months.

Full description

Progerias are rare "premature aging" diseases in which children die of severe atherosclerosis leading to strokes and heart attacks. It is a multisystem disease with objective clinical markers for disease progression. These include abnormalities in growth and body composition, bone mineral density, join function, endocrine function, alopecia, and vascular disease. There is currently no therapy proven effective for any of the progressive and deleterious aspects of this disorder.

Progeria is caused by a gene defect in the gene LMNA, coding for the nuclear protein lamin A. Lamin A is normally expressed by most differentiated cells, and requires posttranslational farnesylation to incorporate into the nuclear membrane. This trial proposes to use three agents (zoledronic acid, pravastatin, and lonafarnib) to inhibit farnesylation of abnormal lamin, the disease causing protein in Progeria. The primary objective of this study is to evaluate the feasibility of administering intravenous zoledronic acid, oral pravastatin and oral lonafarnib, to patients wtih Progeria for a minimum of 4 weeks.

Enrollment

5 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Genetic Diagnosis: All patients must have confirmatory mutational analysis showing mutation in the lamin A gene.
Patients must display clinical signs of progeria as per the clinical trial team.
Patients must be willing and able to come to Boston for appropriate studies and examinations at initiation of study and at week 4 of study.
Patient must have adequate organ and marrow function as defined by study parameters

Exclusion criteria

Other than the drugs used in this protocol, other drugs targeted to treat Progeria are excluded. Drugs to treat symptoms of Progeria are permitted.
Patients must not be taking medications that significantly affect the metabolism of lonafarnib at the time they start lonafarnib.
Patient must have no uncontrolled infection.
Subjects who have known or suspected hypersensitivity to any of the excipients included in the formulation should not be treated.
Patients must not be pregnancy of breast-feeding. Female patients of childbearing potential must have negative serum or urine pregnancy test. Male and female patients of reproductive potential must agree to use a medically accepted form of birth control while on study and up to 10 weeks after treatment. It is permissible for female patients to take oral contraceptives or other hormonal methods while receiving treatment with lonafarnib.